NL-OMON29112CompletedNot Applicable
ECLIPSE extension: An additional 3 year extra follow up to the original 3 year longitudinal prospective study to identify novel endpoints and compare these with forced expiratory volume in 1 second (FEV1) for their ability to measure and predict Chronic obstructive pulmonary disease (COPD) severity and its progression over time (ECLIPSE).
Centrum:CIRO+, expertisecentrum voor chronisch orgaanfalen.Plaats:HornHoofdonderzoeker:Prof. Dr. E.F.M. Wouters0 sites120 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 120
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •A COPD subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Male or female subjects, aged 40-75 years inclusive;
Exclusion Criteria
- •A COPD subject will not be eligible for inclusion in this study only if all of the following criteria apply:
- •1. Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT-scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis);
Investigators
Similar Trials
Completed
Phase 3
Extension 1 to Protocol A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapyheart attackMyocardial infarct10028593NL-OMON32303ovartis30
Active, not recruiting
Phase 1
Extension to the Odanacatib Fracture Trial (PN018)MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersosteoporosisEUCTR2014-002587-33-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
Active, not recruiting
Phase 1
An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
Unknown
Not Applicable
A BLINDED EXTENSION TO 5 YEARS OF A PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF ODANACATIB (MK-0822) TO REDUCE THE RISK OF FRACTURE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN TREATED WITH VITAMIN D AND CALCIUMPER-086-11MERCK SHARP & DOHME PERU S.R.L.,
Active, not recruiting
Not Applicable
Extension 1 to Protocol A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy - NDEssential HypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2008-001306-16-ITOVARTIS FARMA800